-+ 0.00%
-+ 0.00%
-+ 0.00%

Dogwood Therapeutics completes enrollment in Halneuron Phase 2b chemotherapy-induced neuropathic pain trial

PUBT·09/14/2026 12:45:26
Listen to the news
Dogwood Therapeutics completes enrollment in Halneuron Phase 2b chemotherapy-induced neuropathic pain trial
  • Dogwood Therapeutics completed enrollment in its Halneuron Phase 2b trial in chemotherapy-induced neuropathic pain, reaching 239 patients.
  • Topline results have not been presented; the readout is expected in November 2026.
  • The study is designed to determine whether Halneuron reduces pain versus placebo in patients with neuropathic pain following prior chemotherapy.
  • Positive data could support further development of a non-opioid option in an indication with no FDA-approved treatments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140845PRIMZONEFULLFEED9825865) on September 14, 2026, and is solely responsible for the information contained therein.